Christopher Richard Anzalone - 08 Jul 2022 Form 4 Insider Report for ARROWHEAD PHARMACEUTICALS, INC. (ARWR)

Role
Chief Executive Officer, Director
Signature
/s/Christopher Anzalone
Issuer symbol
ARWR
Transactions as of
08 Jul 2022
Net transactions value
$0
Form type
4
Filing time
12 Jul 2022, 19:39:57 UTC
Previous filing
11 Jul 2022
Next filing
29 Sep 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ARWR Common Stock Disposed to Issuer $0 -551,197 -14% $0.000000 3,508,938 08 Jul 2022 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Modification of previously granted award from 800,000 to 248,803.
F2 Includes a total of 1,649,282 shares underlying restricted stock units that may be earned based on the achievement of certain performance and/or market-based goals. If the goals are not met within the required time periods, the awards will be forfeited in part or in whole.